Table 3.

Results of multivariate analysis

	Haploidentical vs HLA-matched sibling			Offspring vs HLA-matched sibling
	HR (95% CI)	P	Probability, %	HR (95% CI)	P	Probability, %
Acute GVHD II-IV at day 100	1.03 (0.78-1.35)	.86	32 vs 26	0.65 (0.44-0.97)	.034	16 vs 23
Acute GVHD III-IV at day 100	1.05 (0.64-1.73)	.84	12 vs 10	0.48 (0.25-0.92)	.028	5 vs 9
Chronic GVHD at 2 y	0.63 (0.48-0.82)	<.001	42 vs 51	0.42 (0.30-0.58)	<.001	28 vs 46
Nonrelapse mortality at 2 y	1.14 (0.77-1.69)	.52	15 vs 13	1.48 (1.05-2.09)	.025	21 vs 17
Relapse at 2 y	1.01 (0.80-1.26)	.97	37 vs 37	1.17 (0.95-1.45)	.14	45 vs 41
Leukemia-free survival at 2 y	1.04 (0.85-1.26)	.70	48 vs 50	1.27 (1.06-1.51)	.008	34 vs 42
Overall survival at 2 y	1.00 (0.81-1.24)	.99	61 vs 61	1.32 (1.10-1.59)	.003	44 vs 51

Bold values represent statistical significance.